Paprocka M, Kuśnierczyk H, Budzyński W, Rak J, Radzikowski C
Arch Immunol Ther Exp (Warsz). 1986;34(3):275-84.
The differences in antitumour effect of /+/R and /-/S enantiomers of both cyclophosphamide and ifosfamide were detected. In the case of ifosfamide in all five tested tumour models (Leukemia L1210, P388, Lewis lung carcinoma, 16/C mammary adenocarcinoma and B16 melanoma) the /-/S form exerted not only higher antitumour effects than /+/R form, but revealed higher therapeutic indices as well. The same appeared to be true for /-/S enantiomer of cyclophosphamide in three models of solid tumours. In L1210 and P-388 ascitic leukemia models /+/R and /-/S cyclophosphamide exerted the same antitumour effect.
检测了环磷酰胺和异环磷酰胺的 /+/R 和 /-/S 对映体在抗肿瘤效果上的差异。就异环磷酰胺而言，在所有五个测试的肿瘤模型（白血病 L1210、P388、Lewis 肺癌、16/C 乳腺腺癌和 B16 黑色素瘤）中，/-/S 形式不仅比 /+/R 形式具有更高的抗肿瘤效果，而且还显示出更高的治疗指数。环磷酰胺的 /-/S 对映体在三种实体瘤模型中似乎也是如此。在 L1210 和 P - 388 腹水白血病模型中，/+ /R 和 /-/S 环磷酰胺具有相同的抗肿瘤效果。
